Finally, RYR also improves endothelial function and arterial stiffness in patients with dyslipidaemias, measured as flow-mediated dilatation (FMD) and pulse-wave velocity (PWV) [162], in addition to reduction of the serum levels of apolipoprotein B, matrix metalloproteinases 2 and 9, and high-sensitivity C-reactive protein [147]. This evidence concerns the gene MMP2 and inherited lipid metabolism disorder.